<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="71060">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180711</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-LY-003</org_study_id>
    <nct_id>NCT02180711</nct_id>
  </id_info>
  <brief_title>An Open-label, Phase 1b Study of Acalabrutinib Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma</brief_title>
  <official_title>ACP 196 Alone or in Combination With Rituximab in Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acerta Pharma, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the safety profile of acalabrutinib alone or in combination with rituximab
      in subjects with relapsed,refractory,or treatment naive Follicular Lymphoma (FL)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (AEs)</measure>
    <time_frame>From first dose of study drug to within 30 days of last dose of study drug</time_frame>
    <description>Number of participants who had experienced at least one treatment emergent AE</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Follicular Lymphoma (FL)</condition>
  <arm_group>
    <arm_group_label>acalabrutinib Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acalabrutinib Regimen 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acalabrutinib Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acalabrutinib Regimen 2 + rituximab for relapsed, refractory, or treatment naive subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acalabrutinib</intervention_name>
    <arm_group_label>acalabrutinib Regimen 1</arm_group_label>
    <arm_group_label>acalabrutinib Regimen 2</arm_group_label>
    <other_name>ACP-196</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab (IV)</intervention_name>
    <arm_group_label>acalabrutinib Regimen 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥ 18 years of age.

          -  A confirmed diagnosis of FL Grade 1, 2, or 3a, which has relapsed after, or been
             refractory to ≥ 1 prior therapy for FL, or subjects who have not previously received
             systemic anticancer therapy for FL., and which requires treatment.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.

          -  Agreement to use contraception during the study and for 30 days after the last dose
             of study drugs if sexually active and able to bear or beget children.

        Exclusion Criteria:

          -  •A life-threatening illness, medical condition or organ system dysfunction which, in
             the investigator's opinion, could compromise the subject's safety, interfere with the
             absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk

          -  Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,
             congestive heart failure, or myocardial infarction within 6 months of screening, or
             any Class 3 or 4 cardiac disease as defined by the New York Heart Association
             Functional Classification, or Qtc &gt;480 msec

          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
             resection of the stomach or small bowel, gastric bypass, symptomatic inflammatory
             bowel disease, or partial or complete bowel obstruction.

          -  Breast feeding or pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Weitzman, MD.</last_name>
    <role>Study Director</role>
    <affiliation>Acerta Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 1, 2016</lastchanged_date>
  <firstreceived_date>June 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bruton tyrosine kinase inhibitor</keyword>
  <keyword>Btk</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>FL</keyword>
  <keyword>acalabrutinib</keyword>
  <keyword>ACP-196</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
